These data indicate that ALDH3A1 contributes to cisplatin resistance in HNSCC and that the targeting of ALDH, specifically, ALDH3A1, appears to be a promising strategy in this disease. Here, ALDH3A1 is linked to head and neck squamous cell carcinoma.